



# Stabilis



## Folate calcium



Noms commerciaux

Antrex	Finlande
Axifolin	Allemagne
Bendafolin	Egypte, Iran
Biofolic	Italie
Calcium leucovorin	Turquie
Calfolex	Italie
Citofolin	Italie
Cromaton	Luxembourg
Dalisol	Colombie, Inde, Mexique
Degalin	Allemagne
Durofolin	Grèce
Etamolin	Pérou
Eurofolic	Allemagne
Fastovorin	Inde
Folcasin	Roumanie
Folical	Colombie
Folidan	Espagne
Folate de calcium	France
Furoic	Italie
Innefol	Mexique
Lederfolin	Grande Bretagne, Irlande, Italie
Ledervorin calcium	Arabie Saoudite, Australie, Belgique, Colombie, Emirats Arabes Unis, Irlande, Luxembourg, Pologne
Leucocalcin	Argentine, Chili
Leucovorin	Allemagne, Autriche, Belgique, Grande Bretagne, Grèce, Hongrie, Pologne, Slovénie, Suisse, Turquie
Neofolin	Allemagne
Novizet	Argentine
Precileucin	Mexique
Prefolic	Italie
Refolinon	Grande Bretagne, Grèce
Rescuvolin	Afrique du sud, Allemagne, Belgique, Colombie, Grèce, Luxembourg, Malaisie, Pays bas, Suède
Ribofolin	Allemagne, Autriche, Iran
Rontafor	Argentine
Sanficine	Grèce
Sanifolin	Italie
Tecnovorin	Colombie, Pérou
Veravorin	Grèce

**Stabilité des solutions**

PVC		1 & 1,5 mg/ml	25°C		4			1287
PVC		1 & 1,5 mg/ml	4°C		4			1287

**Stabilité en mélange**

		0,23 >> 0,95 mg/ml	23°C		Irinotecan : 0,31 >> 0,65 mg/ml	0.5		2340
		0.03 mg/ml	20°C		Floxuridine : 1 mg/ml	48		3694
		0.96 mg/ml	20°C		Floxuridine : 4 mg/ml	48		3694
		0.03 mg/ml	4-8°C		Floxuridine : 1 mg/ml	48		3694
		0.96 mg/ml	4-8°C		Floxuridine : 4 mg/ml	48		3694
		0.03 mg/ml	40°C		Floxuridine : 1 mg/ml	48		3694
		0.96 mg/ml	40°C		Floxuridine : 4 mg/ml	48		3694



## Facteur influençant la stabilité
























				150
--	--	--	--	-----



## Compatibilités

		Folinate calcium : 10 mg/ml	150
		Folinate calcium Bleomycin sulfate	4154
		Folinate calcium Cefamandole nafate	3546
		Folinate calcium Ceftriaxone disodium	3523
		Folinate calcium : 2 mg/ml Cladribine : 0.5 mg/ml	1496
		Folinate calcium : 2 mg/ml	301
		Folinate calcium : 2 mg/ml	1415
		Folinate calcium : 2 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml	921
		Folinate calcium : 2 mg/ml Anidulafungin : 0.5 mg/ml	1982
		Folinate calcium : 2 mg/ml Aztreonam : 40 mg/ml	99
		Folinate calcium : 2 mg/ml Cladribine : 0.015 mg/ml	1496
		Folinate calcium : 2 mg/ml Docetaxel : 0.9 mg/ml	1754
		Folinate calcium : 10 mg/ml Doxorubicin hydrochloride : 2 mg/ml	763
		Folinate calcium : 2 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml	251
		Folinate calcium : 10 mg/ml Droperidol : 2,5 mg/ml	763
		Folinate calcium : 2 mg/ml Etoposide phosphate : 5 mg/ml	1410
		Folinate calcium : 2 mg/ml Filgrastim : 30 µg/ml	244
		Folinate calcium : 0.03 >> 0.960 mg/ml Floxadine : 1 >> 4 mg/ml	3694
		Folinate calcium : 10 mg/ml Fluconazole : 2 mg/ml	496
		Folinate calcium Fluorouracil	3474
		Folinate calcium : 1.54 >> 13.33 mg/ml Fluorouracil : 16.67 >> 46.15 mg/ml	155

		Folinate calcium : 10 mg/ml Fluorouracil : 50 mg/ml		763
		Folinate calcium : 1.54 >> 13.33 mg/ml Fluorouracil : 16.67 >> 46.15 mg/ml		155
		Folinate calcium : 30.8 mg/ml Fluorouracil : 6.5 mg/ml		2130
		Folinate calcium : 30.8 mg/ml Fluorouracil : 50 mg/ml	 	2181
		Folinate calcium : 4 mg/ml Fluorouracil : 6.5 mg/ml	 	2181
		Folinate calcium : 30.8 mg/ml Fluorouracil : 50 mg/ml		2130
		Folinate calcium Fosaprepitant dimeglumine		2295
		Folinate calcium : 10 mg/ml Foscarnet sodium : 24 mg/ml		73
		Folinate calcium : 10 mg/ml Furosemide : 10 mg/ml		763
		Folinate calcium : 2 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Folinate calcium : 2 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Folinate calcium : 10 mg/ml Heparin sodium : 1000 UI/ml		763
		Folinate calcium : 0.27 >> 0.94 mg/ml Irinotecan : 0.30 >> 0.59 mg/ml		2027
		Folinate calcium : 3.6 mg/ml Irinotecan : 0.32 mg/ml		2027
		Folinate calcium : 0,23 >> 0,95 mg/ml Irinotecan : 0,31 >> 0,65 mg/ml		2340
		Folinate calcium : 3,55 >> 3,67 mg/ml Irinotecan : 0,34 >> 0,35 mg/ml		2340
		Folinate calcium : 2 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Folinate calcium : 2 mg/ml Linezolid : 2 mg/ml		1925
		Folinate calcium Magnesium sulfate		3838
		Folinate calcium : 10 mg/ml Methotrexate sodium : 30 mg/ml		150
		Folinate calcium : 10 mg/ml Methotrexate sodium : 25 mg/ml		763
		Folinate calcium : 10 mg/ml Metoclopramide hydrochloride : 5 mg/ml		763
		Folinate calcium Omadacycline		4720
		Folinate calcium Oxaliplatin		3634
		Folinate calcium : 2 mg/ml Oxaliplatin : 0,5 mg/ml		1662
		Folinate calcium Pamidronate disodium		3619

		Folinate calcium Pemetrexed disodium		1914
		Folinate calcium : 2 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Folinate calcium : 2 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Folinate calcium Potassium phosphate		3621
		Folinate calcium : 10 mg/ml Sodium bicarbonate : 14 mg/ml		150
		Folinate calcium : 10 mg/ml Tacrolimus : 1000 µg/ml		479
		Folinate calcium Tedizolid phosphate		3753
		Folinate calcium : 2 mg/ml Teniposide : 0.1 mg/ml		905
		Folinate calcium : 2 mg/ml Thiotepa : 1 mg/ml		249
		Folinate calcium : 10 mg/ml Vinblastine sulfate : 1 mg/ml		763
		Folinate calcium : 10 mg/ml Vincristine sulfate : 1 mg/ml		763
		Folinate calcium Zoledronic acid		3933



## Voie d'administration



## Bibliographie

	Type	Source
73	Revue	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
150	Revue	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
155	Revue	Trissel LA, Martinez JF, Xu QA. Incompatibility of fluorouracil with leucovorin calcium or levoleucovorin calcium. Am J Health-Syst Pharm 1995 ; 52: 710-715.

182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
479	Revue	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
496	Revue	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
763	Revue	Cohen MH, Jonhson-Early A, Hood MA, McKenzie M, Citron ML, Jaffe N, Krasnow SH. Drug precipitation within IV tubing : A potential hazard of chemotherapy administration. Cancer Treat Rep 1985 ; 69: 1325-1326.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1287	Revue	Lecompte D, Bousselet M, Gayrard D, Poitou P. Stability study of reconstituted and diluted solutions of calcium folinate. Pharm Ind 1991 ; 53: 90-94.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	Revue	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Revue	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.

1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1914	Laboratoire	Pemetrexed (Alimta®) - Summary of Product Characteristics Eli Lilly 2016
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2027	Revue	Walker SE, Shirley L, Puodziunas A. Simulation of Y-site compatibility of irinotecan and leucovorin at room temperature in 5% dextrose in water in 3 different containers. Can J Hosp Pharm 2005 ; 58: 212-222.
2130	Revue	Lokiec F, Amirault P, Bonnans H, Gauzan MF, Sauvage N, Santoni J. Stabilité du mélange 5-fluoro-uracil-acide folinique : influence des concentrations, du contenant et de la forme de l'acide folinique. Bull Cancer 1999 ; 86, 11: 946-954.
2181	Revue	Milano G, Renée N. Etude de compatibilité physicochimique 5- fluoro-uracile (nouvelle préparation française) - acide folinique. Bull Cancer 1995 ; 82: 189-195.
2295	Laboratoire	Fosaprepitant (Emend®) - Summary of Product Characteristics Merck Sharp Dohme 2013
2340	Revue	Walker S.E, Law S, Puodziunas A. Simulation of Y-Site Compatibility of Irinotecan and Leucovorin at Room Temperature in 5% Dextrose in Water in 3 Different Containers Can J Hosp Pharm 2005 ; 58, 4: 212-222.
3474	Laboratoire	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3523	Laboratoire	Ceftriaxone (Rocephin®) - Summary of Product Characteristics. Roche 2018
3546	Laboratoire	Cefamandole Flavelab - Résumé des caractéristiques du produit Panpharma SA 2007
3619	Laboratoire	Pamidronate (Pamidronate Actavis®) - Summary of Product Characteristics Wockhardt 2016
3621	Laboratoire	Phosphate dipotassique - Résumé des caractéristiques du produit Renaudin 2008
3634	Laboratoire	Oxaliplatine (Oxaliplatine Accord®) - Résumé des caractéristiques du produit Accord Healthcare 2011
3694	Revue	Smith J.A, Morris A, Duafala M.E, Bertino J.R, Markman M, Kleinberg M. Stability of floxuridine and leucovorin calcium admixtures for intraperitoneal administration. Am J Hosp Pharm 1989 ; 46: 985-989.
3753	Laboratoire	Tedizolid phosphate (Sivextro®) - Summary of Product Characteristics Cubist Pharmaceuticals 2014
3838	Laboratoire	Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007
3933	Laboratoire	Acide zolédronique - (Acide zoledronique Teva Pharma) - Résumé des caractéristiques du produit Teva Laboratoire 2015

4154	Laboratoire	Bleomycin sulfate- Summary of Product Characteristics Accord Health Care 2018
4720	Laboratoire	Nuzyra (amadacycline - Full prescribing infomation. Paratek Pharmaceuticals updated May 2021. Paratek Pharmaceuticals 2021





# Dictionnaire

	Cytoprotecteur		Injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie		Polyvinyl chlorure
	NaCl 0,9% ou glucose 5%		A l'abri de la lumière
	Jour		Stabilité en mélange
	Solvant		Molécule
	Verre		Glucose 5%
	Non précisée		Heure
	Non précisé		Chlorure de sodium 0,9%
	Facteur influençant la stabilité		NaHCO3
	Provoque		Dégradation
	Compatibilités		Précipitation en 30 minutes
	Incompatible		Instabilité chimique
	Incompatibilité non précisée		Précipitation immédiate
	Compatible		NaCl 0,9% + bactériostatique
	Nutrition parentérale (mélange binaire)		Nutrition parentérale (mélange ternaire)
	Précipitation en 24 heures		Aucun
	Turbidité immédiate		Voie d'administration
	Intraveineuse		Perfusion intraveineuse
	Intramusculaire		Bibliographie
	Dictionnaire		